November 26, 2021
AstraZeneca’s systemic lupus erythematosus (SLE) treatment Saphnelo (anifrolumab) hit the Japan market on November 25 upon its NHI price listing, as did Mochida Pharmaceutical’s biosimilar version of Humira (adalimumab), according to company announcements. Saphnelo is a first-in-class type I interferon...read more